Research indicates that commercially produced HMOs can mimic some of the health-promoting effects of the HMOs present in human milk. Produced through fermentation, the DuPont HMO allows makers of infant nutrition products to create formula that is closer to human milk than ever before, and means that formula-fed babies no longer have to miss out on the benefits of these essential components of breast milk. Through our expertise in both infant nutrition and pre- and probiotics, DuPont is uncovering ways in which the health-promoting benefits of HMOs can be utilized not just in infant formula but in dietary supplements, as well, extending the advantages of HMOs across the population.
Over 130 different oligosaccharides have been identified in human milk, with 2’-fucosyllactose (2’-FL) being the most abundant. The DuPont 2’-FL, CARE4U™, has Novel Foods approval in the European Union and GRAS status in the U.S. At >98% 2’-FL, DuPont CARE4U™ is the highest-purity product available on the market today, with superior powder properties that allow for ease in formulation.
It only makes sense that DuPont is a leader in HMOs; it’s in the work we do every day, and have been doing for more than 50 years. Our decades of experience with infant nutrition combined with our leadership in the fields of microbiome science and pre- and probiotics provide an unmatched innovation platform that allows our customers to anticipate and meet the needs of end consumers.
You are welcome to contact us for more information.